Kater AP, et al. - In relapsed/refractory chronic lymphocytic leukemia, the MURANO study showed a significant benefit for progression-free survival (PFS) with fixed-duration venetoclax-rituximab vs bendamustine-rituximab, so researchers reported on minimal residual disease (MRD) kinetics and updated outcomes with all patients off treatment. Patients were randomized to 2 years of venetoclax plus rituximab during the first six cycles, or six cycles of bendamustine-rituximab. Outcomes revealed a continued benefit for venetoclax-rituximab vs bendamustine-rituximab with all patients having finished treatment. They observed durable undetectable MRD (uMRD) rates that predicted longer PFS. This establishes how peripheral blood MRD impacts the benefit of fixed-duration, venetoclax-containing treatment. After 2 years of venetoclax-rituximab, they observed low conversion to detectable MRD and sustained PFS representing how feasible this regimen is.